Search results for "INFARCTION"

showing 10 items of 1208 documents

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): ra…

2004

Summary Background Clopidogrel was superior to aspirin in patients with previous manifestations of atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high-risk subgroups of patients. We aimed to assess whether addition of aspirin to clopidogrel could have a greater benefit than clopidogrel alone in prevention of vascular events with potentially higher bleeding risk. Methods We did a randomised, double-blind, placebo-controlled trial to compare aspirin (75 mg/day) with placebo in 7599 high-risk patients with recent ischaemic stroke or transient ischaemic attack and at least one additional vascular risk factor who were already receiving clopidogrel 75 mg/day. D…

MaleRelative risk reductionTiclopidineHemorrhage030204 cardiovascular system & hematologyKlinikai orvostudományok03 medical and health sciences0302 clinical medicineDouble-Blind MethodRecurrenceRisk FactorsmedicineClinical endpointHumanscardiovascular diseasesMyocardial infarctionRisk factorStrokeAgedAspirinAspirinbusiness.industryAbsolute risk reductionGeneral MedicineOrvostudományokmedicine.diseaseClopidogrelClopidogrel3. Good healthStrokeIschemic Attack TransientAnesthesiaDrug Therapy CombinationFemalebusinessIntracranial HemorrhagesPlatelet Aggregation Inhibitors030217 neurology & neurosurgerymedicine.drug
researchProduct

Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes …

2015

Clinical data on the early and midterm outcomes of bioresorbable vascular scaffolds (BVS) in routine clinical practice are limited. To fill this gap, we report on the early and midterm clinical outcomes of PCI with everolimus-eluting BVS from the large multicentre GHOST-EU registry.Between November 2011 and January 2014, 1,189 patients underwent percutaneous coronary intervention with one or more BVS (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) at 10 European centres. The primary outcome of interest was target lesion failure (TLF), defined as the combination of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularisation (TLR). A total of 1…

MaleReoperationTarget lesionmedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionAntineoplastic AgentsComorbidityCoronary Artery DiseaseAngina PectorisPercutaneous Coronary InterventionRisk FactorsInterquartile rangeInternal medicineAbsorbable ImplantsDiabetes MellitusmedicineHumansCumulative incidenceEverolimusMyocardial infarctionAcute Coronary SyndromeAgedProportional Hazards ModelsTissue Scaffoldsbusiness.industryHazard ratioPercutaneous coronary interventionDrug-Eluting StentsThrombosisMiddle Agedmedicine.diseaseThrombosisSurgeryEuropeTreatment OutcomeCardiovascular DiseasesConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessEuroIntervention
researchProduct

Procedural, Functional and Prognostic Outcomes Following Recanalization of Coronary Chronic Total Occlusions. Results of the Iberian Registry.

2019

Introduction and objectives: There is current controversy regarding the benefits of percutaneous recanalization (PCI) of chronic total coronary occlusions (CTO). Our aim was to determine acute and follow-up outcomes in our setting. Methods: Two-year prospective registry of consecutive patients undergoing PCI of CTO in 24 centers. Results: A total of 1000 PCIs of CTO were performed in 952 patients. Most were symptomatic (81.5%), with chronic ischemic heart disease (59.2%). Previous recanalization attempts had been made in 15%. The mean SYNTAX score was 19.5 +/- 10.6 and J-score was > 2 in 17.3%. A retrograde procedure was performed in 92 patients (9.2%). The success rate was 74.9% and was hi…

MaleReoperationmedicine.medical_specialtyPercutaneousmedicine.medical_treatmentPerforation (oil well)Myocardial Ischemia030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary InterventionPostoperative Complications0302 clinical medicineInternal medicineMyocardial RevascularizationmedicineHumansProspective StudiesRegistriesMyocardial infarctionProspective cohort studyUltrasonography InterventionalAgedPortugalbusiness.industryMortality ratePercutaneous coronary interventionGeneral Medicinemedicine.diseaseTreatment OutcomeCoronary OcclusionSurgery Computer-AssistedSpainCoronary occlusionChronic DiseaseConventional PCICardiologyFemaleCTO Cardiopatía isquémica crónica Chronic ischemic cardiomyopathy Chronic total occlusions IVUS OCT Oclusiones crónicasbusiness
researchProduct

Brain-Derived Neurotrophic Factor But Not Forced Arm Use Improves Long-Term Outcome After Photothrombotic Stroke and Transiently Upregulates Binding …

2008

Background and Purpose— Both application of neurotrophic factors like brain-derived neurotrophic factor (BDNF) and constraint-induced movement therapy like forced arm use have been shown to potentially improve outcome after stroke. The aim of the present study was to check whether postischemic long-term outcome correlates to specific modifications in the abundance of various neurotransmitter receptors. Methods— Adult male Wistar rats were subjected to photothrombotic ischemia and assigned to various treatment groups (n=5 each) with end points at 3 and 6 weeks: (1) ischemic control (saline); (2) BDNF (ischemia, 20 μg BDNF); (3) forced arm use (ischemia, saline, and ipsilateral plaster cast …

MaleRestraint PhysicalMotor ActivityLigandsDownregulation and upregulationNeurotrophic factorsForelimbmedicineAnimalsRats WistarReceptorGABA Agonistsalpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic AcidStrokePhysical Therapy ModalitiesAdvanced and Specialized NursingBrain-derived neurotrophic factorMuscimolbusiness.industryBrain-Derived Neurotrophic FactorGlutamate receptorBrainCerebral Infarctionmedicine.diseaseRatsUp-RegulationStrokemedicine.anatomical_structureReceptors Glutamatenervous systemAnesthesiaExcitatory postsynaptic potentialAutoradiographyNeurology (clinical)Dizocilpine MaleateIntracranial ThrombosisForelimbCardiology and Cardiovascular MedicinebusinessExcitatory Amino Acid AntagonistsNeuroscienceStroke
researchProduct

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI…

2001

Summary Background Despite the use of aspirin, there is still a risk of ischaemic events after percutaneous coronary intervention (PCI). We aimed to find out whether, in addition to aspirin, pretreatment with clopidogrel followed by long-term therapy after PCI is superior to a strategy of no pretreatment and short-term therapy for only 4 weeks after PCI. Methods 2658 patients with non-ST-elevation acute coronary syndrome undergoing PCI in the CURE study had been randomly assigned double-blind treatment with clopidogrel (n=1313) or placebo (n=1345). Patients were pretreated with aspirin and study drug for a median of 6 days before PCI during the initial hospital admission, and for a median o…

MaleRiskAcute coronary syndromePrasugrelTiclopidinemedicine.medical_treatmentMyocardial InfarctionCoronary DiseaseDouble-Blind MethodPreoperative CaremedicineMyocardial RevascularizationHumansMyocardial infarctionProspective Studiescardiovascular diseasesAngioplasty Balloon CoronaryAgedProportional Hazards ModelsManagement of acute coronary syndromeAspirinbusiness.industryPercutaneous coronary interventionGeneral MedicineMiddle AgedClopidogrelmedicine.diseaseSurvival AnalysisClopidogrelLogistic ModelsTreatment OutcomeAnesthesiaConventional PCIFemalebusinessElinogrelPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery di…

2008

Summary. Background: Thrombin activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis. Results on the association between TAFI levels and the risk of coronary artery disease (CAD) are inconsistent. Objectives: We investigated the association between TAFI levels and the risk of cardiovascular events in CAD. Patients/Methods: 1668 individuals with angiographically proven CAD at baseline were followed for a median of 2.3 years, as part of the prospective AtheroGene cohort. Fifty-six deaths from cardiovascular (CV) causes and 35 non-fatal CV events were observed. Results: At baseline, three TAFI measurements were available: one evaluating the total amount of TAFI (t-TAFI), one measuri…

MaleRiskCarboxypeptidase B2medicine.medical_specialtymedicine.medical_treatmentCoronary Artery DiseaseCoronary artery diseaseRisk FactorsInternal medicineFibrinolysismedicineHumansMyocardial infarctionAgedProportional Hazards Modelsbusiness.industryUnstable anginaProportional hazards modelHazard ratioHematologyMiddle Agedmedicine.diseaseCarboxypeptidase BDeath Sudden CardiacCohortCardiologyFemalebusinessProtein Cmedicine.drugJournal of Thrombosis and Haemostasis
researchProduct

Glutathione Peroxidase 1 Activity and Cardiovascular Events in Patients With Coronary Artery Disease

2003

Along with superoxide dismutase, glutathione peroxidase 1 is one of the cellular antioxidant enzymes that have a key role in controlling reactive oxygen species. It uses glutathione to reduce hydrogen peroxide to water and lipid peroxides to their respective alcohols. There are suggestions from in vitro and animal studies that these enzymes could protect against atherosclerosis. This prospective study examined the possibility that relatively high activity of antioxidant enzymes protects against cardiovascular events. The study population included 636 patients suspected of having coronary artery disease who were followed for a median period of 4.7 years. Stable angina was present in 510 pati…

MaleRiskmedicine.medical_specialtyGPX1ErythrocytesAntioxidantmedicine.medical_treatmentCoronary Artery DiseaseGastroenterologyCoronary artery diseaseSuperoxide dismutasechemistry.chemical_compoundSex FactorsInternal medicinemedicineHumansProspective StudiesMyocardial infarctionRisk factorAgedchemistry.chemical_classificationAnalysis of VarianceGlutathione PeroxidaseReactive oxygen speciesbiologySuperoxide DismutaseUnstable anginabusiness.industryGlutathione peroxidaseSmokingObstetrics and GynecologyGeneral MedicineGlutathionemedicine.diseaseSurvival AnalysisEndocrinologychemistryCardiovascular Diseasesbiology.proteinFemalebusinessBiomarkersPeroxidaseObstetrical & Gynecological Survey
researchProduct

Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial.

2014

Association of Mediterranean Diet With Peripheral Artery Disease: The PREDIMED Randomized Trial The role of nutrition in preventing peripheral artery disease (PAD) remains elusive. 1 Mediterranean diets reduce the risk of myocardial infarction and stroke. 2,3. They also may reduce the risk of PAD, but this hypothesis has never been tested in a randomized trial. We assessed the association of Mediterranean diets with the occurrence of symptomatic PAD in an exploratory, nonprespecified analysis of a randomized trial...

MaleRiskmedicine.medical_specialtyMediterranean dietArterial diseaseFood habitsDiseaseDiet Mediterraneanlaw.inventionPeripheral Arterial DiseaseMedicina preventivaMediterranean cookingRandomized controlled triallawInternal medicineCuina mediterràniamedicineHumansNutsPlant OilsMyocardial infarctionOlive OilAgedPreventive medicinebusiness.industryHàbits alimentarisMalalties cardiovascularsGeneral Medicinemedicine.diseasePredimedDietary FatsSurgeryOli d'olivaPrimary PreventionCardiovascular diseasesTreatment Outcome0098-7484Cuina (Nous)FemalebusinessCooking (Nuts)Olive oilJAMA
researchProduct

Ejection Fraction by Echocardiography for a Selective Use of Magnetic Resonance After Infarction

2020

[EN] Background Cardiac magnetic resonance (CMR) permits robust risk stratification of discharged ST-segment-elevation myocardial infarction patients, but its indiscriminate use in all cases is not feasible. We evaluated the utility of left ventricular ejection fraction (LVEF) by echocardiography for a selective use of CMR after ST-segment-elevation myocardial infarction. Methods Echocardiography and CMR were performed in 1119 patients discharged for ST-segment-elevation myocardial infarction included in a multicenter registry. The prognostic power of CMR beyond echocardiography-LVEF was assessed using adjusted C statistic, net reclassification improvement index, and integrated discriminati…

MaleRiskmedicine.medical_specialtyVentricular Ejection FractionTime FactorsInfarctionMagnetic Resonance Imaging CineHeart failurePatient ReadmissionVentricular Function LeftTECNOLOGIA ELECTRONICAVentricular Dysfunction LeftPercutaneous Coronary InterventionPredictive Value of TestsInternal medicinemedicineHumansVentricular ejection fractionRadiology Nuclear Medicine and imagingcardiovascular diseasesMyocardial infarctionProspective StudiesRegistriesAgedEjection fractionmedicine.diagnostic_testbusiness.industryReproducibility of ResultsMagnetic resonance imagingStroke VolumeMiddle Agedmedicine.diseasePrognosisNet reclassification improvementMyocardial infarctionTreatment OutcomeEchocardiographyMagnetic resonanceHeart failurecardiovascular systemCardiologyST Elevation Myocardial InfarctionFemaleCardiology and Cardiovascular MedicinebusinessMacecirculatory and respiratory physiology
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct